The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Risks in new drug development: Approval success rates for investigational drugs
Abstract
Clinical Pharmacology & Therapeutics (2001) 69, 297–307; doi: 10.1067/mcp.2001.115446
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Cost of innovation in the pharmaceutical industry
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991) · Journal of Health Economics · doi:10.1016/0167-6296(91)90001-4 · Cited by 754
Self-citationSuccess rates for new drugs entering clinical testing in the United States
DiMasi, J. A. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90066-7 · Cited by 184
Self-citationDiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1995) · PharmacoEconomics · doi:10.2165/00019053-199507020-00007 · Cited by 169
Self-citationDiMasi, J. A. (2000) · Drug Information Journal · doi:10.1177/009286150003400425 · Cited by 78
Self-citationR&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
DiMasi, J. A., Grabowski, H. G., & Vernon, J. (1995) · International Journal of the Economics of Business · doi:10.1080/758519309 · Cited by 73
Self-citationNew drug development in the United States from 1963 to 1992
DiMasi, J. A., Seibring, M., & Lasagna, L. C. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.78 · Cited by 72
Self-citationNew drug development in the United States, 1963 through 1984
Mattison, N., Trimble, A. G., & Lasagna, L. C. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.35 · Cited by 53
Measuring the Pace of New Drug Development in the User Fee ERA
Kaitin, K. I., & DiMasi, J. A. (2000) · Drug Information Journal · doi:10.1177/009286150003400303 · Cited by 50
Self-citationThe New Drug Approvals of 1996, 1997, and 1998: Drug Development Trends in the User Fee Era
Kaitin, K. I., & Healy, E. M. (2000) · Drug Information Journal · doi:10.1177/009286150003400101 · Cited by 45
Cited by
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Self-citationClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Drug development for neglected diseases: a deficient market and a public-health policy failure
Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., & Ford, N. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09096-7 · Cited by 893
Shuhendler, A. J., Pu, K., Cui, L., Uetrecht, J. P., & Rao, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2838 · Cited by 623
The cost of biopharmaceutical R&D: is biotech different?
DiMasi, J. A., & Grabowski, H. G. (2007) · Managerial and Decision Economics · doi:10.1002/mde.1360 · Cited by 517
Self-citation
Metadata
- Authors
- DiMasi, J. A.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2001-05
- Volume
- 69
- Issue
- 5
- Pages
- 297-307
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2029342376
- Cited by
- 450
- References
- 16
- FWCI
- 43.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risks in new drug development: Approval success rates for investigational drugs. https://app.cochat.ai/papers/10.1067/mcp.2001.115446
- The paper
- DiMasi, J. A. (2001). Risks in new drug development: Approval success rates for investigational drugs. Clinical Pharmacology & Therapeutics. https://doi.org/10.1067/mcp.2001.115446
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
